礼来追加45亿美元投资印第安纳州生产基地 首座基因药物专用工厂落成

美股速递
May 06

制药巨头礼来公司宣布向其印第安纳州生产基地追加45亿美元投资,同时正式启用全美首座专注于基因药物生产的专用设施。

此次大规模资金注入将用于扩大糖尿病药物Mounjaro和减肥疗法Zepbound等关键产品的产能布局。新落成的基因药物工厂采用模块化设计,将专注于RNAi疗法与基因编辑技术的产业化应用。

公司首席执行官戴维·里格斯表示,这项投资将创造200个高技能岗位,并强化美国在生物制药领域的供应链韧性。该基地采用100%可再生能源供电,配备人工智能驱动的质量控制体系。

印第安纳州政府同步宣布为该项目提供税收优惠支持。此次扩产计划预计将使礼来在印第安纳州的总投资规模突破160亿美元,成为美国中西部最大的生物医药制造集群。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10